Trial Profile

A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia

Status: Suspended

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACP 01 (Primary)
Indications Chronic limb-threatening ischemia; Peripheral arterial disorders
Focus Therapeutic Use
Sponsors Hemostemix

26 Jan 2020 According to a Hemostemix Inc. media release, company anticipates that it will conduct a futility analysis for potentially stopping enrolment in the clinical trial when 42 subjects have completed at least 26 weeks of follow-up.
30 Apr 2019 Status changed from recruiting to suspended.
27 Apr 2018 According to a Hemostemix Inc. media release,The Company recently announced that it received FDA approval in the United States in addition to Health Canada approval for its clinical trial in Canada.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com